Peptide
Reference library
Educational peptide reference — research use only.
Research & educational use only
For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.
The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.
Semax
An ACTH-fragment peptide studied in neuroprotection research.
- Half-life (approx.)
- ~minutes (approx.); NA-amidate extended
- Diluent
- Bacteriostatic water (0.9% benzyl alcohol)
- Common vials
- 5, 10 mg
Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.
Overview
Semax is a synthetic ACTH(4-10) analog developed for stroke and cognitive disorders in Russian clinical research. Studies examine BDNF upregulation, attention performance, and neuroprotection after ischemic injury. ACTH(4-10) analog with BDNF upregulation in stroke and cognitive rodent models.
Structure & identity
Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (ACTH 4-10 analog)
- Sequence / structure
- Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (ACTH 4-10 analog)
Mechanism
ACTH(4-10) analog upregulates BDNF and modulates dopaminergic and serotonergic systems. Melanocortin and monoaminergic modulation supplement neurotrophic mechanism literature.
Studies & clinical programs
Stroke neuroprotection trials
Published research models
- Peer-reviewed literature documents endpoints under Stroke neuroprotection trials experimental designs.
Attention task performance
Published research models
- Peer-reviewed literature documents endpoints under Attention task performance experimental designs.
Research models in literature
- Stroke neuroprotection trials
- Attention task performance
Literature highlights
- ACTH(4-10) analog upregulates BDNF in stroke neuroprotection and attention-task rodent studies.
- Dopaminergic and serotonergic modulation examined in CNS pharmacology assays.
- Parent compound for Adamax and component of Semax+Selank research blends.
Combination research notes
Semax + Selank mix; Adamax is a modified analog.
Key targets & pathways
Research areas
Routes in research literature
Also known as
Handling cautions
- Intranasal and injectable forms differ
Stability & storage phases
| Phase | Condition | Guidance |
|---|---|---|
| Lyophilized | Refrigerated (2–8 °C), sealed | Research peptide powder for nasal formulations should remain cold and dry until reconstitution; amidate forms may have distinct published stability guidance. |
| Reconstituted (nasal solution) | Sterile water or bacteriostatic water, refrigerated | Nasal research solutions are often prepared at lower concentrations; use within published stability windows (commonly 1–2 weeks refrigerated). |
| Working aliquots | Single-use nasal sprayer fills or frozen micro-aliquots | Avoid contamination of multi-use bottles in lab settings; sterile technique and cold chain reduce protease and microbial risk. |
Stability windows are formulation-dependent — verify published data and your lab SOP.
Reconstitution reference table
| Vial (mg) | Diluent (mL) | mcg/mL | Units @ 100 mcg | Units @ 250 mcg | Units @ 500 mcg |
|---|---|---|---|---|---|
| 5 | 2 | 2500.0 | 4 | 10 | 20 |
| 10 | 2 | 5000.0 | 2 | 5 | 10 |
U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.
Reconstitution steps
- Allow vial to reach room temperature (15–30 min)
- Swab rubber stopper with alcohol prep pad
- Draw calculated bacteriostatic water into syringe
- Inject diluent slowly down vial wall — do not spray directly onto cake
- Gently swirl until fully dissolved — do not shake vigorously
- Label with date, concentration, and diluent volume
- Refrigerate and use within your lab stability window
Reconstituted per research protocol; intranasal forms differ.
Laboratory record checklist
- Compound identity recorded in lab notebook (name, lot, preparation date)
- Analytical identity cross-checked against published sequence or structure
- Potency or concentration documented from analytical certificate when available
- Purity or HPLC data filed when provided with research material
- Appearance noted: intact lyophilized cake or uniform powder
- Sterility / endotoxin report archived when available
- Storage temperature applied immediately per published stability guidance